EGFR and non-small cell lung carcinoma: Prospective trials and larger molecularly annotated cohorts will be essential to validate whether dose-escalated third-generation EGFR-TKIs can be rationally incorporated into treatment algorithms for EGFR ex20ins-mutant NSCLC.